|
|
| July 16, 2008 |
|
|
Cephalon Inc. (CEPH) - scores hat trick, short squeeze, breakout and new BUY on positive Treanda data |
|
|
|
Biotechnology company Cephalon Inc. (CEPH - FusionIQ Technical Rank 71) said Tuesday its leukemia drug Treanda, in combination with Genentech Inc.'s (DNA -FusionIQ Technical Rank 71) Rituxan, prompted a response in non-Hodgkin's lymphoma patients during a midstage study. The study results were published Tuesday in the Journal of Clinical Oncology and were part of a series of study data filed with the Food and Drug Administration in December. Cephalon has asked the regulatory agency to approve Treanda as a treatment for non-Hodgkin's lymphoma, a type of cancer that starts in a person's lymph system. Rituxan is already approved as a non-Hodgkin's lymphoma and rheumatoid arthritis treatment.
In the Phase II clinical trial, 92 percent of patients with relapsed forms of the cancer responded to the combination therapy. The study involved 66 patients and was one of three studies Cephalon filed with the FDA for the proposed use. The remaining two studies focused on Treanda as a stand-alone treatment for non-Hodgkin's lymphoma.
With a FusionIQ new short squeeze, new timing BUY and breakout along with a point and figure target of $ 83.00 - CEPH shares offer good return potential.
|
|
|
|
|
|
|
|
|